Allergic Bronchopulmonary Aspergillosis in a Patient with Chronic Obstructive Pulmonary Disease
Total Page:16
File Type:pdf, Size:1020Kb
Prim Care Respir J 2012; 21(1): 111-114 CASE-BASED LEARNING Allergic bronchopulmonary aspergillosis in a patient with chronic obstructive pulmonary disease Elias Mira,*Ashok Shaha a Department of Respiratory Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India Originally received 13th April 2011; resubmitted 27th July 2011; revised 16th September 2011; accepted 17th September 2011; online 5th January 2012 Summary Allergic bronchopulmonary aspergillosis (ABPA) is a debilitating lung disease which occurs as a result of interplay between a variety of host and environmental factors. It occurs in certain susceptible individuals who develop hypersensensitivity to the colonised Aspergillus species. ABPA is a complicating factor in 2% of patients with asthma and is also seen in patients with cystic fibrosis. Asthma and chronic obstructive pulmonary disease (COPD) are known to share key elements of pathogenesis. It is well known that ABPA can occur in patients with asthma, but it has recently been reported in patients with COPD as well. We report a 55-year-old male ex-smoker who presented with complaints of exertional breathlessness and productive cough for five years and an episode of haemoptysis four days prior to presentation. Spirometery showed airflow obstruction which was not reversible with bronchodilators. Chest CT scan revealed paraseptal emphysema along with central bronchiectasis (CB) in the right upper lobe and bilateral lower lobes. A type I skin hypersensitivity reaction to Aspergillus species was elicited. He fulfilled the serological criteria for ABPA and was diagnosed as having concomitant COPD and ABPA-CB. The patient was initiated on therapy for COPD along with oral corticosteroids, on which he had remarkable symptomatic improvement. © 2012 Primary Care Respiratory Society UK. All rights reserved. E Mir and A Shah. Prim Care Respir J 2012; 21(1): 111-114 http://dx.doi.org/10.4104/pcrj.2012.00001 Keywords allergic bronchopulmonary aspergillosis, central bronchiectasis, chronic obstructive pulmonary disease Introduction which remain largely unknown. Recently, two reports have Although allergic bronchopulmonary aspergillosis (ABPA) is documented the association of Aspergillus sensitisation and the predominantly a disease of patients with asthma, it is also seen presence of ABPA in patients with COPD.7,8 This is another case in cystic fibrosis.1 Impaired mucocilliary clearance and viscid of a 55-year-old male patient diagnosed as having concomitant sputum in asthmatic airways favours germination of Aspergillus COPD and ABPA. spores. ABPA is an immunologically-mediated lung disease caused by hypersensitivity in a susceptible individual to the Case history presence of Aspergillus hyphae which colonise the airways.2 A 55-year-old non-atopic male, HIV negative and an ex-smoker, Chronic obstructive pulmonary disease (COPD) is a debilitating was referred for evaluation of a 5-year history of progressive disorder recognised less than two centuries ago by Laennec who pulmonary symptoms. His clinical course was characterised by described it as “bronchodilation and emphysema”.3 Though exertional breathlessness, occasional wheezing, and cough with largely seen in smokers, it is now recognised that subjects who thick mucoid sputum. He had seasonal aggravation of his are exposed to biomass fuel smoke are also at risk of developing symptoms, when he produced about a cupful of non-foul COPD.4 Among common diseases afflicting the human smelling yellow sputum daily. An episode of haemoptysis four population, COPD is the only disorder which is still increasing in days before had prompted the referral. Two years prior to prevalence and it is expected to be the third most common presentation, based on his clinical and radiological profile, he cause of death by 2020.5 COPD and asthma are believed to had received antituberculous therapy for nine months (despite share at least some aspects of pathogenesis.6 Surprisingly, the sputum samples being consistently negative for acid fast bacilli) presence of ABPA in COPD is rather unusual, the reasons for with no therapeutic benefit. There were no other co-morbidities. * Corresponding author: Professor Ashok Shah, Department of Respiratory Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, 110007, India. Tel: +91-11-25433783 E-mail: [email protected] PRIMARY CARE RESPIRATORY JOURNAL 111 www.thepcrj.org http://dx.doi.org/10.4104/pcrj.2012.00001 E Mir and A Shah Figure 1. HRCT of thorax showing mucus plugging in the Figure 2. HRCT of thorax showing central bronchiectasis left upper lobe and bilateral paraseptal emphysema (string of pearls appearance) in the right upper lobe He had smoked 20 cigarettes daily for a period of 30 years (30 the presence of the “string of pearls” appearance in the inner pack-years) but had quit five years previously due to an increase two thirds along with peribronchial thickening was visualised in in cough and breathlessness. There was no significant family the right upper lobe (see Figure 2) as well as both the lower history. lobes. The presence of central/proximal bronchiectasis, a feature Although the patient had no acute distress, his arterial SPO2 pathognomic of ABPA, raised the suspicion of ABPA which was at room air, was 93%. There was no cyanosis or clubbing, and further strengthened by the detection of mucoid impaction in diaphragmatic excursion was equal on both sides. On the left upper lobe. Skin prick test against Aspergillus species auscultation, he had prolonged expiration with bibasal coarse was negative; however, intradermal tests against Aspergillus crepitations predominantly on the right side. The haemoglobin fumigatus and A. flavus were positive for type 1 hypersensitivity. level was 14.9 gm/dl, along with a total leucocyte count of Serum precipitins against both these species were positive. 14,580 cells/cu-mm with a differential count of neutrophils Specific IgG against A. fumigatus was also positive. Total serum 73%, lymphocytes 23%, monocytes 3.0% and eosinophils IgE was 645.70 IU/ml as against a normal value of 0 to 14 IU/ml. 1.0%. Absolute eosinophil count was 240 cells/cu-mm. Several The diagnosis of ABPA was based on: a) type I sputum stains and cultures for Mycobacterium tuberculosis as hypersensitivity to intradermal challenge with extracts of A. well as other aerobic organisms were negative. A single sputum fumigatus and A. flavus; b) elevated total serum IgE levels; c) sample was negative for pathogenic fungi. On pulmonary presence of serum precipitins against A. fumigatus and A. function testing, FVC was 2.96 L (93% of predicted), FEV1 was Flavus; d) presence of specific IgG against A. fumigatus; and e) 1.81 L (69% of predicted), FEV1/FVC ratio was 0.61, central/proximal bronchiectasis on the HRCT scan of the FEV0.5/FIV0.5 was 0.35. The total lung capacity was 4.11 L (82% thorax. A diagnosis of COPD stage II with allergic of predicted), residual volume was 1.13 L (63 % of predicted), bronchopulmonary aspergillosis and central bronchiectasis RV/TLC was 27% (87% of predicted) and DLCO was 10.81 (ABPA-CB) was made.1,9 mL/min/mmHg (45% of predicted) and diffusion per unit of The patient was initiated on therapy for COPD as per GOLD alveolar volume was 2.76/min/mmHg (62% of predicted). After guidelines.9 In addition, oral prednisolone (0.5 mg per kg body inhalation of 400 μg of salbutamol, the FVC was 3.16 L (99% of weight) was commenced which was tapered after 15 days to an the predicted) and FEV1 was 1.96 L (75% of predicted). There alternate day regimen. This was further reduced at the rate of was no significant reversibility with bronchodilators. This was 5mg per month after three months. Within a fortnight the indicative of moderate airflow limitation (stage II COPD)9 with patient experienced remarkable relief; his cough and moderately impaired diffusion capacity. breathlessness decreased, while wheezing cleared completely. Chest radiograph, done on presentation, showed Though sputum production persisted, it had considerably hyperinflated lungs associated with cystic areas in the right lower reduced and was no longer regarded as bothersome. There were zone near the hilum. There were no previous chest radiographs no further episodes of haemoptysis. The patient could walk for for comparison. The history of haemoptysis prompted a high- a longer distance without getting symptoms. The arterial SPO2 resolution CT (HRCT) scan of the thorax, which revealed bilateral at room air increased to 96% three months later. As he was from paraseptal emphysema along with mucoid impaction in the left a small town 300 kilometres away, after six months the patient upper lobe (see Figure 1). Central bronchiectasis as evidenced by expressed his wish not to have regular follow-up. PRIMARY CARE RESPIRATORY JOURNAL 112 www.thepcrj.org ABPA in COPD Discussion 38% of asthma patients across the world.25 We have previously ABPA complicates only 2% of patients with asthma.1 Although, reported a positive skin test for hypersensitivity to Aspergillus the pathogenesis of ABPA is largely unknown, a complex antigens in 28.5% of asthma patients. Furthermore, these interplay of host and environmental factors is thought to be patients have a more severe form of asthma compared to those responsible. In some asthma subjects, host factors allow who do not demonstrate skin reactivity to Aspergillus.25 Of 200 colonisation of Aspergillus species in the viscid mucus. ABPA patients with COPD, 17 (8.5%) had Aspergillus hypersensitivity